These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11243603)

  • 1. Use of surrogate endpoints: a practical necessity in lipid-altering and antiatherosclerosis drug development.
    Orloff DG
    Am J Cardiol; 2001 Feb; 87(4A):35A-41A. PubMed ID: 11243603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Laboratory surrogates for anti-atherosclerotic drug development.
    Stein E
    Am J Cardiol; 2001 Feb; 87(4A):21A-26A. PubMed ID: 11243601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism?
    Shepherd J; Olsson AG; Sacks FM; Black DM; Orloff DG; Bilheimer DW
    Am J Cardiol; 1998 Apr; 81(8A):88F-94F. PubMed ID: 9604922
    [No Abstract]   [Full Text] [Related]  

  • 4. Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs.
    Psaty BM; Lumley T
    JAMA; 2008 Mar; 299(12):1474-6. PubMed ID: 18364491
    [No Abstract]   [Full Text] [Related]  

  • 5. Theoretical impact on coronary disease of using a computerized clinical decision support system in the prescription of lipid-lowering treatment.
    Zamora A; Carrion C; Vázquez-Oliva G; Paluzie G; Martín-Urda A; Elosua R
    Rev Esp Cardiol (Engl Ed); 2015 Jan; 68(1):75-8. PubMed ID: 25482341
    [No Abstract]   [Full Text] [Related]  

  • 6. The challenge of regulating development and approval of drugs with pleiotropic action in cardiovascular disease.
    Temple R
    Am J Cardiol; 1998 Apr; 81(8A):5F-9F. PubMed ID: 9604896
    [No Abstract]   [Full Text] [Related]  

  • 7. What kinds of studies should be required to probe efficacy and safety of drugs in special populations?
    LaRosa JC; Sneider GB; Boyle C
    Am J Cardiol; 1998 Apr; 81(8A):84F-87F. PubMed ID: 9604921
    [No Abstract]   [Full Text] [Related]  

  • 8. The Lipoprotein and Coronary Atherosclerosis Study (LCAS) in context: assessing the benefits of lipid-lowering therapy. Introduction.
    Gotto AM
    Am J Cardiol; 1998 Sep; 82(6A):1M. PubMed ID: 9766340
    [No Abstract]   [Full Text] [Related]  

  • 9. [Lipid factors and evolution of the atherosclerotic plaque: review of recent trials].
    Scardi S
    G Ital Cardiol; 1996 Dec; 26(12):1481-93. PubMed ID: 9162677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravascular Ultrasound Studies of Plaque Progression and Regression: Impact of Lipid-Modifying Therapies.
    Shishikura D; Honda S; Andrews J; Nicholls SJ
    Cardiol Clin; 2018 May; 36(2):329-334. PubMed ID: 29609762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical trial endpoints: angiograms, events, and plaque instability.
    Ballantyne CM
    Am J Cardiol; 1998 Sep; 82(6A):5M-11M. PubMed ID: 9766342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reassessing the validity of surrogate markers of drug efficacy in the treatment of coronary artery disease.
    Colatsky TJ
    Curr Opin Investig Drugs; 2009 Mar; 10(3):239-44. PubMed ID: 19333881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronary atherosclerosis stabilization: an achievable goal.
    Maher VM
    Atherosclerosis; 1995 Dec; 118 Suppl():S91-101. PubMed ID: 8821469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation of clinical benefit to metabolic effects in lipid-lowering therapy.
    Herd JA
    Am J Cardiol; 1998 Sep; 82(6A):22M-25M. PubMed ID: 9766344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs.
    Butters J; Brown A; Griffith L; Kim S; Nicholls SJ
    Am J Cardiovasc Drugs; 2017 Dec; 17(6):447-452. PubMed ID: 28432573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decrease the incentives to order lipid panels.
    McConnell M; Downs JR; Good CB
    JAMA Intern Med; 2014 Mar; 174(3):473. PubMed ID: 24590082
    [No Abstract]   [Full Text] [Related]  

  • 17. Introduction: utilization of surrogate markers of atherosclerosis for the clinical development of pharmaceutical agents.
    Davidson MH
    Am J Cardiol; 2001 Feb; 87(4A):1A-7A. PubMed ID: 11243600
    [No Abstract]   [Full Text] [Related]  

  • 18. Decrease the incentives to order lipid panels--reply.
    Virani SS; Ballantyne CM; Petersen LA
    JAMA Intern Med; 2014 Mar; 174(3):473-4. PubMed ID: 24590083
    [No Abstract]   [Full Text] [Related]  

  • 19. Economic implications of lipid-lowering trials: current considerations in selecting a statin.
    Farmer JA
    Am J Cardiol; 1998 Sep; 82(6A):26M-31M. PubMed ID: 9766345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.
    Lonn E
    Pharmacoepidemiol Drug Saf; 2001; 10(6):497-508. PubMed ID: 11828831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.